Supreme Appoints Chris Bechtel to Advisory Board

SEPTEMBER 23, 2014

September 23rd, 2014, Vancouver, BC – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWF – OTC) (“SL” – CSE)is pleased to announce the appointment of Chris Bechtel to its advisory board. Mr. Bechtel brings a wealth of experience in capital markets, start-ups, and medicinal marijuana to the Company.

Mr. Bechtel launched a small business in the oil and gas industry in Houston, Texas in 1983 at the age of 23, which he then grew to revenues of over $30 million in six countries. In 2006, Mr.Bechtel sold his business to Weatherford International, one of the largest global providers of oil and gas services. Mr. Bechtel continues to run the original labs business, as well as otherdivisions for Weatherford, representing a combined staff of 2,500 employees and gross revenues of approximately $500M.

Mr. Bechtel became deeply involved in the marijuana industry after investigating the medical benefits of cannabis for an immediate family member. This led Mr. Bechtel to become a privateinvestor in, and consultant and advisor to, over half-a-dozen companies in the cannabis sector. “We are thrilled by this addition to our team,” said David Stadnyk, President and CEO ofSupreme Pharmaceuticals. “Chris has a deep understanding of the cannabis industry, knows how to grow and run a large multinational business, and brings great strategic value to the Company.” Mr. Bechtel stated, “Growing a fledgling startup into a successful international business was one of the most gratifying experiences of my career; Supreme is well on its way to taking the same journey, and I am excited to be able to support that process in an industry that can bring so many benefits to so many people.”

Contact Information

Investor Relations
430 – 580 Hornby Street
Vancouver BC
V6C 3B6

Phone: (604) 674-2191
Email: info@supreme.ca
Website: www.supreme.ca

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the use of proceeds of the private placement, as well as the Company’s corporate strategy, participation in second tranche by those investors who have submitted subscription agreements to the Company but were not included in the first tranche, and having sufficient subscribers to close a second tranche. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Corporation, including, without limitation, the Company’s ability to complete the remainder of the private placement. Although management of the Corporation believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.